Texxon Holding Limited's (NASDAQ:NPT) Lock-Up Period Set To End on April 20th

Key Points

• Lock-up expiration April 20: Texxon's lock-up period ends on April 20, making shares owned by major shareholders and insiders eligible to trade after an IPO that issued 1,900,000 shares on Oct. 22 at $5.00 (total offering $9.5M).
• Analyst sentiment: Weiss Ratings started coverage with a Sell, Wall Street Zen raised the stock to Hold, and MarketBeat shows a consensus rating of "Sell".
• Recent stock action: NPT opened at $10.31 and was trading up about 5.1%, with a 50‑day SMA of $9.26 and a 12‑month range of $3.14 to $22.38.

Texxon's (NASDAQ:NPT - Get Free Report) lock-up period is set to end on Monday, April 20th. Texxon had issued 1,900,000 shares in its IPO on October 22nd. The total size of the offering was $9,500,000 based on an initial share price of $5.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Analyst Ratings Changes

A number of analysts have recently weighed in on NPT shares. Weiss Ratings started coverage on shares of Texxon in a report on Friday, January 16th. They set a "sell (e-)" rating for the company. Wall Street Zen raised shares of Texxon from a "sell" rating to a "hold" rating in a report on Saturday, March 28th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Sell".

Texxon Trading Up 5.1%

Texxon stock opened at $10.31 on Monday. The company has a 50-day simple moving average of $9.26. Texxon has a 12-month low of $3.14 and a 12-month high of $22.38.

Texxon Company Profile

Texxon Holding Limited is a provider of supply chain management services in the plastics and chemical industries principally in East China. Texxon Holding Limited is based in Shanghai, China.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.